Pregnancy Related
Conditions
Brief summary
In vivo and ex vivo study of trophoblastic angiogenic trophoblastic function in placentas from normal pregnancies, at term
Detailed description
The objective of this study is to better understand the regulation of trophoblast expression of pro- and antiangiogenic factors such as placenta growth factor (PlGF) or Soluble FMS like tyrosin-kinase-1 (sFlt-1), and more particularly on human differentiated trophoblastic cells from healthy placentas. The measurement of the variation in gene and protein expression of placental angiogenic factors will provide a better understanding of their pathophysiology. Secondary objectives are the study of trophoblastic differentiation and placental functions, and the study of the impact of chemical compounds on the biological functions of the placenta. To do this, these healthy placentas may be exposed to different factors that promote the occurrence of specific pregnancy pathologies such as pre-eclampsia and vascular intrauterine growth restriction (IUGR), caused by placental dysfunction. This will make it possible to test molecules and vector approaches targeted directly at the trophoblast, in order to consider therapeutic targets, which do not exist to date.
Interventions
None listed
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Centre Hospitalier Intercommunal Creteil
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Pregnancies with scheduled cesarean delivery \>37 weeks of amenorrhea: * strictly normal pregnancies * complicated pregnancies of gestational diabetes, insulin-treated or not * complicated pregnancies due to pregnancy cholestasis * spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI) pregnancies with or without oocyte donation
Exclusion criteria
* Patient's opposition * Age \< 18 years old * Women under the protection of justice * Multiple pregnancy * Known major fetal malformation * Pre-eclampsia and intrauterine growth retardation * Placental insertionnomaly * Type 1 diabetes * HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load * Patient in labour at the time of Caesarean section * Patient whose medical history results in medication being taken in pregnancy courses that may interfere with the biology of the trophoblast (immunomodulators in case of autoimmune diseases, anti-rejection drugs in case of transplant patients)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of placental angiogenic factors | day 0 | Variation in the gene and protein expression of placental angiogenic factors on healthy placentas |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of sFlt-1 (Soluble FMS like tyrosin-kinase-1) | day 1 | Sflt-1 levels when the placenta is exposed to factors that promote the development of vascular pregnancy diseases |
| Level of PlGF (Placental Growth Factor) | day 1 | PlGF levels when the placenta is exposed to factors that promote the development of vascular pregnancy diseases |
Countries
France
Contacts
Primary Contactcamille JUNG, MD
Outcome results
None listed